Avance Clinical teams with trial sites in Korea

Avance Clinical has signed deals with three clinical trial sites in Korea, citing a desire to expand its local presence.

The Australia-based CRO announced the accords at the recent KoNECT 2024 conference, describing them as an “important milestone in the company’s strategic expansion across the Asia-Pacific region.”

The three sites are: the CHA University Bundang Medical Center, a 1,000-bed hospital with a focus on research; the Korea University Medicine centre in Seoul; and the Dong-A University Hospital, Clinical Trial Center in Busan.

Avance CEO Yvonne Lungershausen framed the deals as part of the CROs ongoing expansion effort.

“As Avance Clinical continues to grow its global footprint, these partnerships with respected institutions will further enhance our ability to offer flexible, efficient, and high-quality clinical trial services in the Asia-Pacific region.”

Avance’s regional director, Jessica Han, echoed this, adding, “With its highly sophisticated healthcare infrastructure and regulatory framework, South Korea offers an ideal environment for clinical trials.

“These MOU [memorandum of understanding] signings will not only solidify our collaborations with key institutions but also provide our clients with seamless access to high-quality clinical trial sites and patient populations in the region. We look forward to forging deeper connections and driving growth in Asia.”

Expansion

The Korean deals follow just a few months after Avance added some 2,000 clinical trial sites in North America to its network.

A month earlier Avance signed a MOU with Nanjing, China-based Mid-Ship Biomedical, a CRO that provides preclinical trial services in the country.

At the time, Liahna Toy, vice president of commercial business development at Avance, cited the deal as a major regional expansion.

“This MOU marks a pivotal moment in our efforts to bridge the gap between the Chinese and Australian biotech markets.”

DepositPhotos/Firststar